Therapeutic Advances in Endocrinology and Metabolism最新文献

{"title":"From traditional to novel: a national cohort study on the predictive value of C-reactive protein-triglyceride-glucose-obesity composite parameters for cardiovascular disease.","authors":"Mengjie Zhao, Xujie Wang, Xuexue Zhang, Yan Yan, Zirong Li, Fang Lu, Qiuyan Li","doi":"10.1177/20420188261471668","DOIUrl":"10.1177/20420188261471668","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) is the leading cause of mortality worldwide. The C-reactive protein-triglyceride-glucose (CTI) index captures metabolic inflammation and insulin resistance, while obesity indices reflect adiposity-related cardiometabolic risk. However, the predictive value of combining CTI with obesity indices for CVD remains unclear.</p><p><strong>Objectives: </strong>To examine the prognostic utility of CTI combined with established and novel obesity indicators for CVD, and to benchmark their predictive efficacy.</p><p><strong>Design: </strong>Nationally representative prospective cohort study.</p><p><strong>Methods: </strong>Using data from the China Health and Retirement Longitudinal Study (CHARLS), a nationally representative prospective cohort, 7847 adults aged 45 years and above without baseline CVD were enrolled. CTI was calculated from C-reactive protein, fasting blood glucose, and triglycerides (TG); each obesity index was combined with CTI to form composite parameters (CTI-body mass index (CTI-BMI), CTI-waist circumference (CTI-WC), CTI-waist-to-height ratio (CTI-WHtR), CTI-body roundness index (CTI-BRI), CTI-weight-adjusted waist index (CTI-WWI), CTI-Chinese visceral adiposity index (CTI-CVAI), CTI-a body shape index (CTI-ABSI)). We employed Cox proportional hazard models, restricted cubic spline analyses, Kaplan-Meier survival plots, ROC curve evaluations, and weighted quantile sum (WQS) regression to examine the links and prognostic utility of each metric with incident CVD across baseline and cumulative exposure tiers.</p><p><strong>Results: </strong>Over a 9-year follow-up period, 1938 new-onset CVD cases were documented. Following multivariable adjustment, each CTI-obesity composite metric showed a significant positive link to CVD risk (<i>p</i> < 0.05). Moreover, all CTI‑obesity composite parameters showed stronger associations with CVD than CTI alone. CTI‑CVAI demonstrated the relatively best predictive accuracy among the evaluated indices, though absolute discriminatory ability remained modest (baseline area under the ROC curve (AUC): 0.596; cumulative AUC: 0.600). Trajectory clustering found that, versus the well-managed group, the poorly managed subgroup had 21%-71% higher CVD risk (max 71% for CTI-WC). WQS regression indicated that CRP and obesity indices (especially CVAI) were the major contributors in the mixed exposure; cumulative exposure WQS analysis showed that cumulative TG and cumulative obesity parameters contributed the most.</p><p><strong>Conclusion: </strong>CTI combined with obesity indices, particularly CTI-CVAI, was associated with modestly improved predictive ability for CVD risk compared with CTI alone. This parameter may offer incremental information for CVD risk stratification by integrating metabolic inflammation and visceral fat markers.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261471668"},"PeriodicalIF":7.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13462511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitators, barriers, and interventions for exercise adherence in patients with prediabetes: a mixed-methods systematic review.","authors":"Yijia Yuan, Min Deng, Huan Chen, Xianying Lu, Xinyu Chen, Dingxi Bai, Huiting Gao, Chaoming Hou, Jing Gao","doi":"10.1177/20420188261469945","DOIUrl":"10.1177/20420188261469945","url":null,"abstract":"<p><strong>Background: </strong>As a critical preclinical stage of type 2 diabetes (T2D), prediabetes necessitates urgent lifestyle interventions to halt disease progression. Despite robust evidence supporting the efficacy of exercise in improving glycemic control, exercise adherence remains suboptimal among individuals with prediabetes.</p><p><strong>Objectives: </strong>This review aimed to identify barriers and facilitators to exercise adherence in individuals with prediabetes while also extracting evidence-based behavior change techniques (BCTs) that may enhance physical activity maintenance.</p><p><strong>Design: </strong>Mixed-methods systematic review.</p><p><strong>Data sources and methods: </strong>A comprehensive literature search was performed in 10 databases from inception to November 2024. Guided by the JBI Manual for Evidence Synthesis, a convergent integrated approach was used to map barriers and facilitators to the Behavior Change Wheel (BCW) and Theoretical Domains Framework (TDF). TDF domains were ranked by frequency across studies, while adherence-promoting interventions were mapped to BCW intervention functions and BCTs. Barriers were systematically linked to BCW intervention functions and BCTs to guide implementation design.</p><p><strong>Results: </strong>A total of 36 studies were included, consisting of 9 qualitative studies, 24 quantitative studies (15 randomized controlled trials, 5 cross-sectional studies, and 4 quasi-experimental studies), and 3 mixed-methods studies. The synthesis identified \"lack of time,\" \"lack of appropriate exercise equipment or venues,\" and \"health-related physical limitations\" as predominant barriers. Conversely, \"perceived health benefits,\" \"social support,\" and \"tools or methods to help with exercise adherence\" emerged as key facilitators. These factors were mapped to five primary TDF domains: reinforcement, environmental context and resources, behavioral regulation, social influences, and skills. Furthermore, seven intervention functions derived from the BCW were linked to 21 BCTs.</p><p><strong>Conclusion: </strong>This review highlights multifaceted determinants of exercise adherence in individuals with prediabetes and identifies theory-informed strategies to address barriers to adherence. Determinants supported more consistently across studies may provide a stronger basis for intervention development, whereas less frequently reported findings should be interpreted more cautiously.</p><p><strong>Trial registration: </strong>PROSPERO CRD42024605588.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261469945"},"PeriodicalIF":7.8,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.","authors":"Azza O Alawad, Tarig H Merghani, Tarig E Fadelelmoula, Nasir Abdelrafie Elamin, Shahenaz Satti, Alhiedi Ali Edris, Alwaleed Hakim, Rima Fathi El-Hindi, Ahmed Abdalla Alhaj-Ali, Wasil Elnour Ibrahim, Muhanad Ahmed Mustafa, Maymouna Mohieldin Sirelkhatim, Hany Hatim Ahmed, Nadia Osman Yousif","doi":"10.1177/20420188261469947","DOIUrl":"10.1177/20420188261469947","url":null,"abstract":"<p><p>The risk of cardiovascular disease is significantly increased by both type 2 diabetes mellitus (T2DM) and obesity through overlapping pathways involving insulin resistance, dyslipidemia, systemic inflammation, and endothelial dysfunction. Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has shown significant glycemic and weight-reducing effects and is increasingly recognized as a cardiometabolic therapy that extends beyond glucose control. This narrative review summarizes clinical and translational evidence about the cardiovascular and metabolic benefits of tirzepatide and the biologic mechanisms that may underpin its effects. Tirzepatide has consistently shown high improvements in key indicators of glycemic control and body weight across the SURPASS program in patients with T2DM and the SURMOUNT program in patients with obesity. Benefits include marked reduction in glycated hemoglobin and cardiovascular risk factors, such as systolic and diastolic blood pressure, atherogenic lipid parameters, visceral adiposity, and several inflammatory biomarkers. Dual incretin signaling seems to increase endothelial function by enhancing the bioavailability of nitric oxide, reducing oxidative stress, inhibiting pro-inflammatory pathways such as nuclear factor kappa B, and favorably modulating adipokine profiles, collectively supporting cardiovascular protection. Promising data suggest symptomatic and functional improvements in obesity-related heart failure with preserved ejection fraction. Reductions in major adverse cardiovascular events are currently under investigation in dedicated outcome trials, including the SURPASS Cardiovascular Outcomes Trial. Overall, tirzepatide provides broad cardiometabolic benefits, making it a promising treatment in the changing landscape of cardiometabolic disease management.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261469947"},"PeriodicalIF":7.8,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.","authors":"Mohamed Mustaf Ahmed, Rahmatullah Nazari, Zhinya Kawa Othman, Shuaibu Saidu Musa, Olalekan John Okesanya, Uthman Okikiola Adebayo, Francesco Branda, Abdullahi Hassan Elmi, Don Eliseo Lucero Prisno","doi":"10.1177/20420188261472587","DOIUrl":"10.1177/20420188261472587","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists have transformed obesity pharmacotherapy by producing substantial weight loss and, for semaglutide in patients with established cardiovascular disease, reducing major cardiovascular events. Integrating these therapies into primary care is constrained by gaps in provider training, clinical inertia, weight bias, high treatment costs, and fragmented insurance coverage. Racial and ethnic minority groups, low-income communities, and publicly insured patients are less likely to receive or fill prescriptions despite the disproportionate burden of obesity-related diseases. This narrative review examines primary care readiness, structural determinants of access, disparities in prescribing and use, real-world adherence, and policy options for these drugs. Without coordinated action, these therapies may reinforce a two-tiered treatment landscape in which access reflects socioeconomic advantages rather than clinical needs. Equitable implementation will require aligned reforms in coverage and pricing, workforce development, person-centered care, and long-term treatment support.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261472587"},"PeriodicalIF":7.8,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148607644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of gout attributable to high BMI (1990-2021) and causal link with obesity: a GBD and Mendelian randomization study.","authors":"Baofeng Wu, Ziang Liu, Zekai Chen, Chunhuan Hong, Yi Zhang, Yunfeng Liu","doi":"10.1177/20420188261465525","DOIUrl":"https://doi.org/10.1177/20420188261465525","url":null,"abstract":"<p><strong>Background: </strong>High body mass index (BMI ⩾25 kg/m²) is a critical driver of the global gout epidemic. We aimed to characterize the evolving burden of gout attributable to high BMI and establish the potential causal links between varying obesity grades and gout risk.</p><p><strong>Objectives: </strong>We aimed to characterize the evolving burden of gout attributable to high BMI and establish the potential causal links between varying obesity grades and gout risk.</p><p><strong>Design: </strong>An observational global epidemiological analysis and a bidirectional two-sample Mendelian randomization (MR) study.</p><p><strong>Methods: </strong>Utilizing Global Burden of Disease (GBD) 2021 data, we analyzed disability-adjusted life years (DALYs) and age-standardized DALY rates across 204 countries. Trends were assessed via Joinpoint regression, decomposition, and inequality analyses. Future trajectories were projected using Bayesian age-period-cohort models. Bidirectional MR evaluated the causal impact of Class 1-3 obesity on gout, adjusting for multiple comparisons.</p><p><strong>Results: </strong>From 1990 to 2021, global DALYs for high BMI-related gout increased 2.26-fold, with a 56.9% rise in age-standardized DALY rates. While High-socio-demographic index (SDI) regions face the highest absolute burden, the fastest growth occurred in low-middle SDI regions, indicating a geographic shift. A significant \"age-shift\" was observed, with the burden increasingly affecting younger males. Epidemiological changes were the primary drivers. MR analysis provided evidence supporting a potential causal relationship between Class 1 and 3 obesity and gout (all odds ratios > 1), with no evidence of reverse causality. Projections suggest that the global age-standardized DALY rates will reach 7.1 per 100,000 by 2040.</p><p><strong>Conclusion: </strong>The global burden of high BMI-related gout is escalating, driven by epidemiological transitions and rising risks in younger men. Genetic evidence supports weight management as a fundamental preventive pillar. Targeted interventions, particularly in rapidly urbanizing regions, are urgently needed to curb this health threat.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261465525"},"PeriodicalIF":7.8,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13491354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148797756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic pancreatitis and pancreatogenic type 3c diabetes risk: a systematic review and meta-analysis.","authors":"Mengtay Makashova, Amin Tamadon, Yerlan Bazargaliyev, Khatimya Kudabayeva, Raikul Kosmuratova, Nadiar M Mussin, Ramazon Safarzoda Sharoffidin","doi":"10.1177/20420188261469942","DOIUrl":"10.1177/20420188261469942","url":null,"abstract":"<p><strong>Background: </strong>Chronic pancreatitis (CP) progressively destroys pancreatic parenchyma and predisposes patients to pancreatogenic type 3c diabetes mellitus (T3cDM).</p><p><strong>Objectives: </strong>We conducted a systematic review and meta-analysis of cohort studies enrolling adults with clinically and/or instrumentally confirmed CP and no pre-existing diabetes at baseline.</p><p><strong>Design: </strong>Systematic review and meta-analysis of cohort studies.</p><p><strong>Data sources and methods: </strong>Scopus, Web of Science Core Collection, and PubMed were searched from inception to August 2025. Random-effects models estimated pooled incidence of new-onset diabetes and the proportion requiring insulin. Prespecified subgroup analyses were stratified by follow-up duration (<60 months, 60-120 months, >120 months). Meta-regression explored demographic, behavioral, and clinical moderators.</p><p><strong>Results: </strong>Nineteen studies met the inclusion criteria and contributed to the primary meta-analysis of incident diabetes after CP. The pooled incidence of diabetes was 30% (95% CI: 27-34; <i>I</i>² = 94.8%), with a prediction interval of 15%-49%. Exploratory follow-up-stratified analysis suggested a time-dependent increase: 18% (95% CI: 14-22) at <60 months, 25% (95% CI: 15-35) at 60-120 months, and 44% (95% CI: 24-66) at >120 months (<i>p</i> for subgroup differences = 0.0184). Among patients who developed diabetes, 59% (95% CI: 46-71; 7 studies; <i>I</i>² = 91.7%) required insulin therapy. Meta-regression did not identify statistically significant study-level moderators, although pancreatic calcification showed a non-significant positive trend.</p><p><strong>Conclusion: </strong>CP is associated with a substantial and time-dependent incidence of diabetes; however, the pooled estimates should be interpreted cautiously because the included studies were observational and highly heterogeneous. These findings support long-term glycemic monitoring and careful classification of pancreatogenic diabetes in patients with CP, while optimal screening intervals and treatment timing require further prospective evidence.</p><p><strong>Trial registration: </strong>PROSPERO CRD420251136931.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261469942"},"PeriodicalIF":7.8,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of electronic order set implementation in patients with diabetic ketoacidosis: a retrospective cohort study.","authors":"Hassan Mitwally, Eman Al Hmoud, Zeana AlKudsi, Mohamed Saad, Farah Zahrah, Mustafa Seidahmed, Mahmud Ben Masoud, Rasha Al-Anany","doi":"10.1177/20420188261460595","DOIUrl":"10.1177/20420188261460595","url":null,"abstract":"<p><strong>Background: </strong>Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes requiring timely insulin administration and dynamic fluid/electrolyte management.</p><p><strong>Objectives: </strong>The aim of this study is to assess the effectiveness of an electronic order set (PowerPlan) on time to DKA resolution compared to individual order prescribing.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>This study included patients (⩾14 years old) with DKA, identified via electronic medical records, and matched to pre- and post-PowerPlan groups. The primary outcome was time to DKA resolution. Secondary outcomes included hospital length of stay, appropriateness of initial intravenous fluids, and insulin infusion. Safety outcomes included the number of hypoglycemia, hyperkalemia, and hypokalemia events until DKA resolution.</p><p><strong>Results: </strong>Of 226 matched patients (113 per group), baseline characteristics were comparable. The post-implementation group achieved faster DKA resolution (median 10.6 vs 12.6 h; <i>p</i> = 0.002), higher adherence to fluid and insulin protocols, and shorter hospital stay (3.15 vs 3.61 days; <i>p</i> = 0.04). Safety outcomes were similar, with fewer hypoglycemic events and comparable electrolyte abnormalities.</p><p><strong>Conclusion: </strong>Implementation of the DKA PowerPlan significantly shortened time to resolution and reduced hospital stay without compromising safety. These findings support standardized electronic order sets to enhance efficiency and quality of DKA management.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261460595"},"PeriodicalIF":7.8,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.","authors":"Antonia-Therese Kietaibl, Marcus Säemann, Stefan Scherr, Kadriye Aydinkoc-Tuzcu, Peter Fasching, Lisa Frühwald","doi":"10.1177/20420188261463401","DOIUrl":"10.1177/20420188261463401","url":null,"abstract":"<p><p>Automated insulin delivery (AID) is the gold standard of treatment for type 1 diabetes mellitus (T1DM). However, little data on the use in people on peritoneal dialysis (PD) exist. To share real-world experience on the use of AID (Medtronic MiniMed 780G SmartGuard and Guardian 4 continuous glucose monitoring system) in a woman living with type 1 diabetes on PD, we report the implementation despite the complex setting of type 1 diabetes with multiple diabetes-associated complications, PD, visual impairment, and a complete language barrier. Glycemic control 14 days before the start of AID on multiple daily injections and 9 months after the conversion is presented. AID might be a safe and promising therapeutic option for individuals with T1DM and end-stage kidney disease requiring PD. Further research is needed to demonstrate both safety and efficacy in this special population, and assessment of patient-reported outcome measures.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261463401"},"PeriodicalIF":7.8,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients.","authors":"Figen Guzelgul, Nihan Bozkurt, Merve Catak, Kubra Sahin, Marwa Abdelmageed, Shahab Ahmed Salih Gezh, Sadegul Savkin","doi":"10.1177/20420188261460573","DOIUrl":"10.1177/20420188261460573","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of diabetes is affected by a complex interplay between numerous environmental and genetic factors. While single-nucleotide polymorphisms (SNPs) are not directly used as biomarkers of the disease, they can be considered an important guide for determining predisposition.</p><p><strong>Objective: </strong>To investigate the roles of raftlin, malondialdehyde (MDA), superoxide dismutase (SOD), and the vitamin D receptor (VDR) BsmI (rs1544410 A>G) polymorphism, in the clinical progression of type 2 diabetes mellitus (T2DM).</p><p><strong>Design: </strong>A retrospective observational case-control study.</p><p><strong>Methods: </strong>A total of 300 subjects were included in the study: 104 with T2DM, 85 with prediabetes, and 111 healthy controls. The VDR BsmI polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, while serum MDA, SOD, and raftlin were analyzed via the enzyme-linked immunosorbent assay (ELISA) method.</p><p><strong>Results: </strong>No statistically significant differences were observed in the allelic and genotype frequencies of the VDR gene BsmI polymorphism between T2DM prediabetes patients and controls (<i>p</i> = 0.97, <i>p</i> = 0.58, respectively). MDA levels were higher, while raftlin levels were lower in patients with T2DM and prediabetes compared to controls (<i>p</i> < 0.05). Within the T2DM cohort, HbA1c (<i>p</i> = 0.014), MDA (<i>p</i> = 0.001), and raftlin (<i>p</i> < 0.001) differed significantly between the BB and bb genotypes, with a positive correlation between the bb genotype and HbA1c (<i>p</i> = 0.008, <i>r</i> = 0.287). Receiver operating characteristic (ROC) analysis revealed raftlin's diagnostic potential among T2DM patients with the BB and bb genotypes, with an area under the curve (AUC) of 0.839, a specificity of 69.2%, and a sensitivity of 81.5%.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is the first study to demonstrate that raftlin exhibits significant diagnostic efficacy in individuals with the bb genotype within a clinical T2DM cohort.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261460573"},"PeriodicalIF":7.8,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13376486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multinational Survey: The Impact of Living With Obesity on Well-Being: A Plain Language Summary.","authors":"Catalina Cernica, Julie Hviid Hahn-Pedersen, Tracy Zvenyach","doi":"10.1177/20420188261459852","DOIUrl":"https://doi.org/10.1177/20420188261459852","url":null,"abstract":"<p><p>What is this summary about? Obesity is a complex, long-term condition that affects far more than a person's physical health. It can impact emotional well-being (how happy a person feels), mental health (how a person feels about daily life), relationships, and quality of life. In a study of 7,000 people across a range of body sizes, researchers found that people living with obesity reported lower self-esteem (lower satisfaction with oneself), higher levels of depression (feeling sad or hopeless) and stress, and greater feelings of loneliness compared with those not living with obesity. Many also shared that they received less empathy (less understanding) and faced more stigma (judgment). These findings highlight the need for well-rounded care that focuses on empathy in all areas of well-being for people living with obesity. What is the purpose of this plain language summary? The number of people worldwide living with excess weight or obesity (people who weigh more than what is considered healthy) has increased in recent decades. Researchers in this study asked people living with obesity about their wellbeing. People interviewed in this study also shared their experiences with judgment (stigma) or understanding about their obesity. This study shows how greatly weight-related stigma can impact the well-being of people living with obesity.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261459852"},"PeriodicalIF":7.8,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}